{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Angiogenesis > OsimertinibCAS：1421373-65-0
Storage：Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Yellow to yellowish brown Solid
Qty：
Size：
| CAS | 1421373-65-0 |
| Name | Osimertinib |
| Molecular Formula | C28H33N7O2 |
| Molecular Weight | 499.61 |
| Solubility | Soluble in DMSO ≥20mg/mL |
| Purity | ≥98% |
| Appearance | Yellow to yellowish brown Solid |
| Storage | Powder:2-8℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD27988062 |
| SMILES | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC |
| InChIKey | DUYJMQONPNNFPI-UHFFFAOYSA-N |
| InChI | InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13，16-18H，1，14-15H2，2-6H3，(H，30，36)(H，29，31，32) |
| PubChem CID | 71496458 |
| Target Point | EGFR |
| Passage | Angiogenesis;Protein Tyrosine Kinase/RTK |
| Background | Osimertinib is a third-generation EGFR inhibitor that inhibits T790M resistance mutations produced by second-generation EGFR inhibitors with irreversible and oral activity. Osimertinib has antitumor activity and can be used in the treatment of EGFR mutated non-small cell lung cancer. |
| Unit | Bottle |
| Specification | 5mg 10mg 20mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
